Pneumococcal serotypes associated with invasive disease in under five children in India & implications for vaccine policy

被引:31
作者
Balaji, V. [1 ]
Jayaraman, Ranjith [1 ]
Verghese, Valsan Philip [2 ]
Baliga, P. R. [1 ]
Kurien, T. [3 ]
机构
[1] Christian Med Coll & Hosp, Dept Microbiol, Vellore 632004, Tamil Nadu, India
[2] Christian Med Coll & Hosp, Child Hlth Unit, Vellore 632004, Tamil Nadu, India
[3] Christian Med Coll & Hosp, Dept Gen Med, Vellore 632004, Tamil Nadu, India
关键词
Invasive pneumococcal disease; PCV; pneumococcal serotypes; vaccine coverage; STREPTOCOCCUS-PNEUMONIAE DISEASE; CONSENSUS RECOMMENDATIONS; CONJUGATE VACCINES; SURVEILLANCE; 19A; IMMUNIZATION; INFECTIONS; PREVENTION; COUNTRIES; NETWORK;
D O I
10.4103/0971-5916.166588
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: Streptococcus pneumoniae is a major cause of morbidity and mortality especially in children less than five years, particularly in India. We present data on S. pneumoniae infections in children less than five years age group, with response to its serotype distribution, antibiotic resistance profile and available vaccines expected coverage. Methods: Children aged less than five, who were suspected for invasive pneumococcal disease were included in the study and their sterile body fluids were investigated for the presence of S. pneumoniae. Invasive S. pneumoniae isolates from sterile body fluids were identified by bile solubility and optochin susceptibility test. Pneumococcal serotyping was performed with co-agglutination technique and reconfirmed with multiplex PCR. Results: The most common pneumococcal serotypes causing invasive infections in children less than five years of age were 14, 19F, 5, 6A and 6B. Of the 114 S. pneumoniae isolates studied, 110 (96.4%) were non-susceptible to co-trimoxazole and 30 per cent were non-susceptible to erythromycin, 5.2 per cent of the isolates were non-susceptible to penicillin and only 0.8 per cent was non-susceptible to cefotaxime. Interpretation & conclusions: Our results indicate that PCV-10 can protect against 64 per cent of serotypes causing invasive pneumococcal infections. Use of PCV-13 in this region can provide increase in protection upto 74.6 per cent against serotypes causing invasive pneumococcal infections. Incorporating PCV-13 in the Universal Immunization Programme may provide incremental protection against IPD serotypes in the southern region of the country.
引用
收藏
页码:286 / 292
页数:7
相关论文
共 30 条
[1]  
[Anonymous], 2005, MMWR Morb Mortal Wkly Rep, V54, P893
[2]   Invasive Pneumococcal Disease among Children in Rural Bangladesh: Results from a Population-Based Surveillance [J].
Arifeen, Shams E. ;
Saha, Samir K. ;
Rahman, Sayedur ;
Rahman, Kazi Mizanur ;
Rahman, Syed Moshfiqur ;
Bari, Sanwarul ;
Naheed, Aliya ;
Mannan, Ishtiaq ;
Seraji, M. Habibur R. ;
Ahmed, Nawshad U. ;
Hassan, M. Shameem ;
Huda, Nazmul ;
Siddik, Ashraf Uddin ;
Quasem, Iftekhar ;
Islam, Maksuda ;
Fatima, Kaniz ;
Al-Emran, Hassan ;
Brooks, W. Abdullah ;
Baqui, Abdullah H. ;
Breiman, Robert F. ;
Sack, David ;
Luby, Stephen P. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 :S103-S113
[3]   Surveillance of Invasive Pneumococcal Disease in Colombo, Sri Lanka [J].
Batuwanthudawe, R. ;
Karunarathne, K. ;
Dassanayake, M. ;
de Silva, S. ;
Lalitha, M. K. ;
Thomas, K. ;
Steinhoff, M. ;
Abeysinghe, N. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 :S136-S140
[4]   Overview of the disease burden of invasive pneumococcal disease in Asia [J].
Bravo, L. C. .
VACCINE, 2009, 27 (52) :7282-7291
[5]   Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the Intermountain West:: Emergence of nonvaccine serogroups [J].
Byington, CL ;
Samore, MH ;
Stoddard, GJ ;
Barlow, S ;
Daly, J ;
Korgenski, K ;
Firth, S ;
Glover, D ;
Jensen, J ;
Mason, EO ;
Shutt, CK ;
Pavia, AT .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (01) :21-29
[6]  
Castillo D., 2011, WHO MANUAL, V2nd
[7]  
Center for Disease Control and Prevention, 2014, PROT MULT PCR S PNEU
[8]  
Clinical and Laboratory Standards Institute, 2020, Performance Standards for Antimicrobial Susceptibility Testing
[9]   Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? [J].
Hausdorff, William P. ;
Hoet, Bernard ;
Schuerman, Lode .
BMC PEDIATRICS, 2010, 10
[10]  
Hausdorff WP, 2005, LANCET INFECT DIS, V5, P83, DOI 10.1016/S1473-3099(05)01280-6